Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amicus Therapeutics 47 Hulfish Street Princeton NJ 08542 USA

www.amicusrx.com Employees: 517 P: 609-662-2000 F: 609-662-2001

Description:

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.'The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.'The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.

Key Statistics

Overview:

Market Capitalization, $K 2,865,550
Enterprise Value, $K 3,006,420
Shares Outstanding, K 298,806
Annual Sales, $ 399,360 K
Annual Net Income, $ -151,580 K
Last Quarter Sales, $ 141,520 K
Last Quarter Net Income, $ -6,730 K
EBIT, $ 13,900 K
EBITDA, $ 24,390 K
60-Month Beta 0.68
% of Insider Shareholders 2.20%
Float, K 292,232
% Float 97.80%
Short Volume Ratio 0.33

Growth:

1-Year Return -11.85%
3-Year Return -11.20%
5-Year Return -8.49%
5-Year Revenue Growth 337.65%
5-Year Earnings Growth 61.65%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.10 on 11/06/24
Next Earnings Date N/A
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Qtr 300.00%
EPS Growth vs. Prev Year 157.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

FOLD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -15.97%
Return-on-Assets % -3.17%
Profit Margin % -37.96%
Debt/Equity 2.18
Price/Sales 7.12
Price/Cash Flow N/A
Price/Book 15.91
Book Value/Share 0.60
Interest Coverage -1.99
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar